Elicio Therapeutics：Phase 2 AMPLIFY-7P DFS 终点分析预计于 1H 2026

来源摘录

EX-99.1 2 elicioq325prdraft_111320.htm EX-99.1 elicioq325prdraft_111320 Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates  In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025.  Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival (“DFS”); event-driven primary DFS analysis now anticipated in 1H 2026.  Since the beginning of Q3 2025, the Company has raised gross proceeds of app

SEC 8-K